Selank: resolve the entity first
Selank is the synthetic tuftsin analogue TKPRPGP. Selank’s tuftsin-derived identity and proposed GABAergic–immune signalling remain distinct from Semax, benzodiazepines and generic anxiolytic claims.
Selank · Clinical molecule review
Selank: mechanism, evidence and clinical review.
Clinic Terrain reviews Selank molecule by molecule, identity, mechanism, human evidence, individual fit and the verification required before any protocol could be proposed.
For people asking whether Selank is relevant to a defined objective, not looking for an unverified vial or an automatic protocol.Request a Selank review →
Identity · the synthetic tuftsin analogue TKPRPGP
Evidence · molecule-specific monograph
Decision · physician reviewed
Product · verified before any proposal
Scientific dossier
Read the complete biochemistry-first monograph.
The scientific page treats identity, target architecture, signalling, pharmacology, physiology, counterevidence and falsification independently from the service offer.
What Selank can plausibly act on
The relevant causal architecture is GABAergic, immune and neurotrophic signalling hypotheses with route-specific evidence. Route-specific and mechanistic findings cannot establish comparative anxiolytic efficacy, long-term safety or suitability for an undiagnosed symptom.
The decision inputs that change the answer
The consultation distinguishes transient stress, anxiety disorder, sleep disruption, medication effects and neurological symptoms, while preserving established psychiatric or medical care.
What must be resolved before any Selank protocol
Clinical relevance is only the first gate. A proposed route would also require a lawful pathway, current availability, exact formulation and presentation, responsible source, current lot, matching analytical documentation, receipt and storage controls. Clinic Terrain does not infer those facts from the molecule name or from a monograph.
How response to Selank is adjudicated
A predeclared anxiety, sleep or functional endpoint is followed beside sedation, activation, adherence and contextual stressors; a single calm day is not a clinical conclusion. Continue, refine and stop decisions remain attached to the physician-reviewed record.
Direct answers
What to resolve before requesting this molecule.
Can Clinic Terrain assess a Selank request?
Yes. The clinical team can review the molecule, evidence and individual question. Assessment does not promise that a product is indicated, lawfully available, verified or supplied. Selank access follows clarification of anxiety, sleep, medication and neurological context. It is not treated as a peptide version of a benzodiazepine or as interchangeable with Semax.
Does Clinic Terrain publish a price for Selank?
No current product price is published for Selank. A commercial quote would be inappropriate before the lawful route, exact presentation, current availability and matching product documentation are resolved.
What evidence cannot be inferred for Selank?
Route-specific and mechanistic findings cannot establish comparative anxiolytic efficacy, long-term safety or suitability for an undiagnosed symptom.
What would Clinic Terrain monitor with Selank?
A predeclared anxiety, sleep or functional endpoint is followed beside sedation, activation, adherence and contextual stressors; a single calm day is not a clinical conclusion.
Evidence position
The evidence is applied to the specific clinical question. It supports an individual assessment; it does not replace diagnosis or guarantee an outcome.
Sources used for this page
Primary sourceUchakina et al. Zh Nevrol Psikhiatr. 2008;108:71–75. ↗Selank is a synthetic heptapeptide related to tuftsin.Primary sourceVolkova et al. Front Pharmacol. 2016;7:31. ↗Proposed actions include GABAergic modulation, neurotrophic pathways and immune–neural communication.Primary sourceMedvedev et al. Zh Nevrol Psikhiatr. 2014;114:17–22. ↗A comparative report in 60 patients with anxiety and somatoform disorders described anxiolytic and mild cognitive effects relative to phenazepam, but accessible reporting leaves randomisation, blinding, allocation and endpoint hierarchy insufficiently resolved.Regulatory guidanceWHO: good storage and distribution practices for medical products ↗This guidance defines supply-chain controls only. It does not prove the identity, purity, sterility or suitability of a specific product or lot.Primary sourcePanikratova et al. Functional connectomic approach to Selank and Semax effects. Dokl Biol Sci. 2020. ↗Small human reports establish administration and a signal worth studying; they do not establish broad anxiolysis, cognitive enhancement or injectable efficacy.Regulatory guidanceICH: harmonised pharmaceutical quality guidelines ↗This framework explains what a quality system must establish. It is not analytical evidence for a Clinic Terrain product or lot.Your first message · Where you are + what you need help with